孟鲁司特联合布地奈德治疗过敏性鼻炎的疗效及其对患者tIgE与sIgE的影响  

Curative Effect of Combined Treament of Montelukast and Budesonide on Allergic Rhinitis and its Impact on tIgE and sIgE

作　　者：谢骊[1,2] 刘涛[2] 谭龙益[2] 

机构地区：[1]同济大学医学院,上海200940 [2]上海市第一人民医院宝山分院检验科,上海200940

出　　处：《标记免疫分析与临床》2016年第9期992-994,1019,共4页Labeled Immunoassays and Clinical Medicine

摘　　要：目的研究孟鲁司特联合布地奈德治疗过敏性鼻炎的临床疗效和对患者tIgE与sIgE的影响。方法选取我院2011年7月到2015年5月间呼吸科及耳鼻喉科收治的160例过敏性鼻炎患者;随机分为观察组80例和对照组80例,观察组给予孟鲁司特联合布地奈德进行治疗,对照组单纯给予布地奈德进行治疗。比较两组患者治疗前后临床症状评分,同事对比两组治疗前后血清总免疫球蛋白E(TIg E)和特异性免疫球蛋白E(SIg E)浓度。结果观察组和对照组治疗前症状评分分别为11.21±3.46分、11.22±3.29分,治疗后观察组和对照组临床症状评分分别为1.96±0.79分、3.96±0.93分。两组间治疗前症状评分差异无统计学意义(P>0.05),治疗后均明显下降,而观察组下降更加明显,差异其有统计学意义(t=3.23,P<0.05)。观察组和对照组治疗前TIg E、SIg E水平分别为469.25±36.92k U/L、486.32±32.26k U/L、29.96±16.92k U/L、29.42±17.26 k U/L,差异无统计学意义(P>0.05);治疗后分别为249.35±27.13KU/L、362.28±35.18k U/L、12.35±7.13k U/L、14.28±6.18k U/L,两组间治疗后差异有统计学意义(P<0.05)。结论孟鲁司特联合布地奈德能够明显减轻过敏性鼻炎患者气道炎症反应,同时降低由Ig E介导的I型变态气道反应炎症,降低血清总免疫球蛋白E(TIg E)和特异性免疫球蛋白E(SIg E)浓度,是一种高效的治疗方法,值得在临床中推广使用。Objective To study the clinical curative effect of combined treatment of Montelukast, and budesonide on allergic rhinitis. Methods We selected 160 patients with allergic rhinitis who were treated in the department of respiratory and otolaryngology of our hospital from July 2011 to May 2015. Patients were divided into two groups, observation group 80 cases and control group 80 cases. The observation group was given Montelukast plus budesonide. The control group was given budesonide treatment alone. Patient symptoms and clinical assessments were compared between the two groups before and after the treatment and serum total immunoglobulin E （tIgE） and specific immunoglobulin E （sIgE） concentration was compared between two groups before and after treatment. Results Observation group symptom score before treatment was 11.21 ± 3.46, after treatment was 1.96 ± 0.79. The symptom score in control group was 11.22 ± 3.29 before treatment, 3.96 ± 0.93 after treatment. Symptom scores before treatment between the two groups had no statistical difference （ P 〉 0.05 ）, after treatment scores were significantly lower （ P 〈 0.05 ）. tIgE and sIgE levels in observation group and control group before treatment were 469.25 ＋ / - 36.92 kU/L, 486.32 ＋/-32.26 kU/L, and 29.96 ＋/- 16.92 kU/L, 29.42 ＋/- 17. 26 kU/L. There was no statistical difference （ P 〉 0.05 ）. After treatment, tIgE and sIgE levels in two groups were 249.35 ＋ / - 27.13 KU/L, 362.28 ＋/-35. 18 kU/L and 12. 35 ＋/-7. 13 kU/L, 14. 28 ＋/-6. 18 kU/L. tlgE and sIgE levelsbetween the two groups after treatment were statistically different （P 〈 0. 05 ）. Conclusion Montelukast combined with budesonide can significantly reduce airway inflammation in allergic rhinitis patients. At the same time it reduces IgE mediated type I allergic airway inflammation reaction. We also showed that the joined treatment can reduce the total serum immunoglobulin E and specific immunoglobulin E. This is a highly effective regimen and worthy of furthe

关 键 词：孟鲁司特 布地奈德 过敏性鼻炎 tIgE与sIgE 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]